EGFR and non-small cell lung carcinoma: To clarify the mechanisms of osimertinib tolerance, we performed receptor-tyrosine kinase (RTK) array analysis comparing AXL-low-expressing (HCC4006 and H3255) and AXL-high-expressing (PC-9) EGFR-mutated NSCLC cell lines treated with or without osimertinib for 72 h.